{"product_id":"semaglutide","title":"Semaglutide","description":"\u003cdiv class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Characteristics\" id=\"characteristics\"\u003eCharacteristics\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cfigure class=\"table\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd\u003eC187H291N45O59\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAS Number\u003c\/td\u003e\n\u003ctd\u003e910463-68-2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolar Mass\u003c\/td\u003e\n\u003ctd\u003e4113.641 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmino Acid Sequence\u003c\/td\u003e\n\u003ctd\u003eHis-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-COOH\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynonyms\u003c\/td\u003e\n\u003ctd\u003eNN9535, NN9934, GLP1, GLP-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolubility\u003c\/td\u003e\n\u003ctd\u003eWater-soluble\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganoleptic Profile\u003c\/td\u003e\n\u003ctd\u003eWhite to off-white powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposition\u003c\/td\u003e\n\u003ctd\u003eLyophilized powder - requires reconstitution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"How does Semaglutide work?\" id=\"how-does-semaglutide-work\"\u003eHow does Semaglutide work?\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eSemaglutide exerts its effects through several interconnected mechanisms:\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003eGLP-1 Receptor Activation: Semaglutide binds to and activates GLP-1 receptors, which are expressed in various tissues including pancreatic islets, the gastrointestinal tract, and the central nervous system. This activation initiates intracellular signaling cascades, primarily through cyclic AMP (cAMP) and protein kinase A (PKA) pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ePancreatic Effects: In pancreatic β-cells, semaglutide enhances glucose-stimulated insulin secretion by increasing intracellular cAMP levels and promoting calcium influx. Simultaneously, it inhibits glucagon secretion from α-cells, contributing to improved glucose homeostasis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCentral Nervous System Effects: Semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamus and brainstem. This central action modulates appetite-regulating neurons, leading to reduced food intake and increased satiety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGastrointestinal Effects: By slowing gastric emptying, semaglutide helps to reduce postprandial glucose excursions and contributes to the sensation of fullness.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiovascular System: While the exact mechanisms are not fully elucidated, semaglutide appears to have direct and indirect effects on the cardiovascular system. These may include improvements in endothelial function, reduction in inflammation, and beneficial changes in lipid metabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMetabolic Rate: Some studies suggest that semaglutide may influence energy expenditure, potentially through effects on brown adipose tissue activation, although this area requires further investigation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHepatic Effects: Semaglutide has been shown to reduce liver fat content in patients with non-alcoholic fatty liver disease (NAFLD), possibly through improvements in insulin sensitivity and lipid metabolism.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe combined action of these mechanisms results in improved glycemic control, weight loss, and potential cardiovascular benefits observed in clinical studies. The complex interplay of these effects underscores the importance of continued research to fully elucidate the therapeutic potential and physiological impacts of semaglutide and other GLP-1 receptor agonists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Research\" id=\"research\"\u003eResearch\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGlucose Homeostasis: Semaglutide stimulates glucose-dependent insulin secretion from pancreatic β-cells while suppressing glucagon release from α-cells. This dual action contributes to improved glycemic control in individuals with type 2 diabetes mellitus (T2DM).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite Regulation: By acting on GLP-1 receptors in the hypothalamus and other brain regions associated with appetite control, semaglutide reduces food intake and promotes satiety.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBody Weight Reduction: Through its effects on appetite and potentially other metabolic pathways, semaglutide has been shown to facilitate significant weight loss in clinical studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiovascular Effects: Research indicates that semaglutide may have beneficial effects on cardiovascular risk factors, including improvements in lipid profiles and blood pressure.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Side Effects\" id=\"side-effects\"\u003eSide Effects\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eThe most common side effects associated with semaglutide include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eNausea Vomiting Diarrhea Abdominal pain Constipation Headache\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInjection site reactions (for injectable formulations)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese side effects are generally mild to moderate and tend to diminish over time with continued use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"Summary\" id=\"summary\"\u003eSummary\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003cp\u003eSemaglutide represents a significant advancement in GLP-1 receptor agonist research, offering a potent tool for investigating the multifaceted roles of GLP-1 signaling in metabolic and cardiovascular physiology. Its demonstrated efficacy in glycemic control, weight management, and potential cardiovascular benefits makes it a valuable subject for ongoing research in the treatment of T2DM, obesity, and related metabolic disorders. As investigations continue, semaglutide may provide insights into novel therapeutic strategies for addressing the growing global burden of metabolic and cardiovascular diseases.\u003c\/p\u003e\n\u003ch3\u003eStorage \u0026amp; Handling\u003c\/h3\u003e\n\u003ch4\u003eRecommended Storage Conditions\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003eStore refrigerated at 2–8°C unless otherwise specified\u003c\/li\u003e\n\u003cli\u003eProtect peptide material from moisture and excessive light\u003c\/li\u003e\n\u003cli\u003eKeep vials sealed until laboratory use\u003c\/li\u003e\n\u003cli\u003eAvoid repeated freeze-thaw cycles after reconstitution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eLaboratory Handling Practices\u003c\/h5\u003e\n\u003cp\u003eSemaglutide peptide should be handled using appropriate sterile laboratory techniques and standard research protocols to maintain sample integrity and experimental reliability.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eFrequently Asked Questions About Semaglutide\u003c\/h3\u003e\n\u003ch4\u003eWhat is Semaglutide?\u003c\/h4\u003e\n\u003cp\u003eSemaglutide is a synthetic peptide analog related to glucagon-like peptide-1 (GLP-1) and is referenced in peptide signaling and receptor interaction research literature.\u003c\/p\u003e\n\u003ch4\u003eHow is Semaglutide supplied for research?\u003c\/h4\u003e\n\u003cp\u003eSemaglutide research compounds are typically supplied as lyophilized powder in sealed laboratory vials to maintain stability during storage and transportation.\u003c\/p\u003e\n\u003ch4\u003eWhy are peptides supplied in lyophilized form?\u003c\/h4\u003e\n\u003cp\u003eLyophilization removes water from peptide solutions under controlled vacuum conditions, producing a stable dry peptide preparation suitable for long-term storage and laboratory preparation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-4 scroll-mt-20 text-2xl font-semibold leading-[2rem] tracking-tight md:scroll-mt-24\" data-scroll-name=\"References\" id=\"references\"\u003eReferences\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"strapi-content max-w-none text-[#4B5563]\"\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8775408\/\"\u003eLaurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci. 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34942372\/\"\u003eChao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34305810\/\"\u003eSmits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33667417\/\"\u003eDavies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36322838\/\"\u003eWeghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36578889\/\"\u003eTan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33625476\/\"\u003eWadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34706925\/\"\u003eSingh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32213703\/\"\u003eGabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nøhr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilvásy-Szabó A, Willenbrock H, Secher A, Knudsen LB, Hogendorf WFJ. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37672701\/\"\u003eDandona P, Chaudhuri A, Ghanim H. Semaglutide in Early Type 1 Diabetes. N Engl J Med. 2023.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28266779\/\"\u003eBlundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35131037\/\"\u003eKadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35650449\/\"\u003eMahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm Res. 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33969456\/\"\u003eOvergaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36945734\/\"\u003eMcGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JB. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36655300\/\"\u003eWharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT. Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP 5. Obesity (Silver Spring). 2023.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33269530\/\"\u003eFriedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36568109\/\"\u003eNiu S, Chen S, Chen X, Ren Q, Yue L, Pan X, Zhao H, Li Z, Chen X. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37192005\/\"\u003eChuong V, Farokhnia M, Khom S, Pince CL, Elvig SK, Vlkolinsky R, Marchette RC, Koob GF, Roberto M, Vendruscolo LF, Leggio L. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023.\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv data-scroll-name=\"Certificate of Analysis (COA)\" class=\"mb-8 flex flex-col md:mb-16 md:flex-row md:gap-x-16\"\u003e\n\u003cdiv class=\"md:w-[30%] md:min-w-[30%]\"\u003e\n\u003ch2 class=\"mb-6 text-2xl font-semibold leading-[2.25rem] tracking-tight md:my-0\" id=\"certificates\"\u003eCertificate of Analysis (COA)\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"flex w-full flex-row md:gap-x-8 flex-wrap gap-x-0 gap-y-4\"\u003e\n\u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv class=\"w-1\/2 md:w-fit\"\u003e\n\u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0820\/1266\/8123\/files\/image.jpg?v=1774432584\"\u003e\u003c\/div\u003e\n\u003ch1 class=\"relative overflow-hidden rounded-none\"\u003eHLPC\u003c\/h1\u003e\n\u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0820\/1266\/8123\/files\/image_1.jpg?v=1774432638\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"relative overflow-hidden rounded-none\"\u003e\n\u003cp\u003e**Semaglutide 5mg Lyophilized Powder Vial – Dosage, Reconstitution, and Usage Instructions**\u003c\/p\u003e\n\u003cp\u003e### 1. Reconstitution (Mixing) Instructions for 5mg Vial\u003cbr\u003eUse only **Bacteriostatic Water for Injection (BAC water)**. Never use regular water or saline.\u003c\/p\u003e\n\u003cp\u003e**Recommended reconstitution (standard 2.5 mg\/mL concentration):**  \u003cbr\u003e- Add **2.0 mL** of BAC water to one 5mg vial.  \u003cbr\u003e- Resulting concentration: **2.5 mg\/mL**\u003c\/p\u003e\n\u003cp\u003e**Step-by-step reconstitution (sterile technique):**  \u003cbr\u003e1. Allow the 5mg vial and BAC water vial to reach room temperature (about 10 minutes).  \u003cbr\u003e2. Wipe both vial tops with an alcohol swab.  \u003cbr\u003e3. Using a sterile syringe, draw **2.0 mL** of BAC water.  \u003cbr\u003e4. Slowly inject the water along the inner wall of the 5mg vial (do not spray directly onto the powder).  \u003cbr\u003e5. Gently swirl the vial until the powder fully dissolves (do not shake).  \u003cbr\u003e6. Store the reconstituted solution in the refrigerator (2–8°C \/ 36–46°F). Use within **28 days**.\u003c\/p\u003e\n\u003cp\u003e### 2. Standard Dosage Titration Schedule (Weight-Loss Protocol)\u003cbr\u003eAdminister **once weekly** by subcutaneous injection on the same day each week.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth data-col-size=\"lg\"\u003eWeek\u003c\/th\u003e\n\u003cth data-col-size=\"sm\"\u003eWeekly Dose\u003c\/th\u003e\n\u003cth data-col-size=\"lg\"\u003ePurpose\u003c\/th\u003e\n\u003cth data-col-size=\"sm\"\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"lg\"\u003eWeeks 1–4\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e0.25 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003eStarting dose\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003eAllows body to adjust; side effects common\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"lg\"\u003eWeeks 5–8\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e0.5 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003eFirst increase\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"lg\"\u003eWeeks 9–12\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e1.0 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003eIntermediate dose\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"lg\"\u003eWeeks 13–16\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e1.7 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003eNear maintenance\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"lg\"\u003eWeek 17 onward\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e2.4 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003eMaintenance dose (max)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003eMay stay at 1.7 mg if tolerated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDose increases should only occur if the previous dose is well tolerated. If side effects are severe, delay the increase by 1–4 weeks.\u003c\/p\u003e\n\u003cp\u003e### 3. Precise Dosage Calculation Table (for 2.5 mg\/mL concentration)\u003cbr\u003eUse a U-100 insulin syringe (0.3–0.5 mL, 31–32G recommended).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth data-col-size=\"sm\"\u003eDesired Weekly Dose\u003c\/th\u003e\n\u003cth data-col-size=\"md\"\u003eVolume to Inject (mL)\u003c\/th\u003e\n\u003cth data-col-size=\"lg\"\u003eUnits on U-100 Syringe\u003c\/th\u003e\n\u003cth data-col-size=\"sm\"\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"sm\"\u003e0.25 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"md\"\u003e0.10 mL\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003e10 units\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003eStarting dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"sm\"\u003e0.5 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"md\"\u003e0.20 mL\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003e20 units\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"sm\"\u003e1.0 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"md\"\u003e0.40 mL\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003e40 units\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"sm\"\u003e1.7 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"md\"\u003e0.68 mL\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003e68 units\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd data-col-size=\"sm\"\u003e2.4 mg\u003c\/td\u003e\n\u003ctd data-col-size=\"md\"\u003e0.96 mL\u003c\/td\u003e\n\u003ctd data-col-size=\"lg\"\u003e96 units\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\"\u003eMaintenance dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e**Formula for any dose:**  \u003cbr\u003e**Volume (mL) = Desired dose (mg) ÷ Concentration (2.5 mg\/mL)**  \u003cbr\u003e**Units = Volume (mL) × 100**\u003c\/p\u003e\n\u003cp\u003e### 4. Subcutaneous Injection Method\u003cbr\u003e- **Injection sites** (rotate each week): Abdomen (at least 2 inches from navel), outer thigh, or back of upper arm.  \u003cbr\u003e- **Steps**:  \u003cbr\u003e  1. Wipe the injection site and vial top with an alcohol swab.  \u003cbr\u003e  2. Draw the exact dose into the syringe and remove air bubbles.  \u003cbr\u003e  3. Pinch a fold of skin, insert the needle at a 45–90° angle, and inject slowly.  \u003cbr\u003e  4. Hold for 5–10 seconds, then withdraw the needle and press the site gently.  \u003cbr\u003e- Dispose of used needles in a sharps container.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Pure peptides","offers":[{"title":"2mg*5vials","offer_id":48509999153371,"sku":null,"price":99.0,"currency_code":"USD","in_stock":true},{"title":"5mg*5vials","offer_id":48509999186139,"sku":null,"price":165.0,"currency_code":"USD","in_stock":true},{"title":"10mg*5vials","offer_id":48509999218907,"sku":null,"price":285.0,"currency_code":"USD","in_stock":true},{"title":"20mg*5vials","offer_id":48509999251675,"sku":null,"price":385.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0820\/1266\/8123\/files\/2026-03-25_163806.png?v=1774429055","url":"https:\/\/ueuhk.com\/products\/semaglutide","provider":"Pure peptides","version":"1.0","type":"link"}